Original Research
Published on 08 Nov 2023
Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
- 1,762 views
- 2 citations